logo

Aveo Pharmaceuticals, Inc. (AVEO)



Trade AVEO now with
  Date
  Headline
12/7/2017 7:06:51 AM AVEO Updates To Tivozanib And Ficlatuzumab Programs; Enrollment Complete In Phase 2 Portion Of Phase 1/2 TiNivo Trial
11/15/2017 4:01:43 AM EUSA Pharma And AVEO Oncology Announce First Commercial Launch Of FOTIVDA (tivozanib)
11/13/2017 10:07:53 AM B. Riley FBR Initiates AVEO Pharmaceuticals, Inc. (AVEO) At Buy With $5 Price Target
11/7/2017 7:19:26 AM AVEO Oncology Q3 Net Loss $26.4 Mln Or $0.22 Per Share
11/6/2017 4:02:17 AM AVEO Oncology, EUSA Pharma Announce Promising Phase 1 Results From Phase 1/2 TiNivo Study Of Tivozanib And Nivolumab
9/20/2017 7:13:16 AM AVEO Oncology, EUSA Pharma Announce TiNivo Combination Study Opt-in
9/13/2017 7:01:49 AM AVEO Oncology Reports Receipt Of $4 Mln R&D Payment From EUSA Pharma Related To Approval Of FOTIVDA
8/28/2017 6:18:03 AM AVEO Oncology Announces FOTIVDA Approved In EC For Advanced Renal Cell Carcinoma
8/9/2017 7:12:10 AM AVEO Oncology Q2 Net Loss $33.3 Mln Or $0.30/Shr
6/27/2017 9:06:53 AM AVEO Oncology Announces $14 Mln In Aggregate Gross Proceeds From Hercules Credit Facility
6/23/2017 8:02:08 AM AVEO Oncology Reports Positive CHMP Opinion For Tivozanib As Treatment Of Advanced Renal Cell Carcinoma
6/20/2017 7:03:11 AM AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma Reaches Enrollment Target
6/8/2017 7:05:56 AM AVEO Oncology: Phase 1/2 TiNivo Trial Of Tivozanib And Opdivo (nivolumab) In RCC Advances To Phase 2
5/16/2017 7:04:46 AM AVEO Oncology Appoints Matthew Dallas As CFO, Effective June 1
5/15/2017 9:31:45 AM AVEO Oncology Issues Statement Regarding The Passing Of Its Lead Director Henri Termeer
5/8/2017 7:17:34 AM AVEO Oncology Unveils Receipt Of USPTO Notice Of Allowance Related To AV-353
5/4/2017 7:26:02 AM AVEO Oncology Q1 Net Loss $8.8 Mln Or $0.12/shr Vs. Net Loss $7.7 Mln Or $0.13/shr Last Year
4/13/2017 8:08:27 AM AVEO Oncology Submits Response To Tivozanib Marketing Authorization Application Day 180 List Of Outstanding Issues